Kennedy Giulia C
Known title: Chief Scientific & Med OfficerCIK: 0001769333
Associated companies
Transaction History
| VCYT | ▼ Sell | Open Market | 1,023 | $28K | 12/6/2022 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 1,008 | $29K | 12/2/2022 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 2 | $29 | 11/11/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 2 | $59 | 11/11/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,023 | $26K | 11/4/2022 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 1,008 | $19K | 9/2/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,028 | $27K | 8/5/2022 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 2 | $13 | 8/5/2022 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 2 | $21 | 8/5/2022 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 1 | $5 | 8/5/2022 | View on chart |
| VCYT | ▲ Buy | Grant | 10,702 | $0 | 8/5/2022 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 1,008 | $18K | 6/2/2022 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 4,407 | $26K | 3/4/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 17,059 | $425K | 3/4/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 5,844 | $150K | 3/4/2022 | View on chart |
| VCYT | ▼ Sell | Open Market | 100 | $3K | 3/4/2022 | View on chart |
| VCYT | ▲ Buy | Grant | 42,412 | $0 | 3/3/2022 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 10,337 | $288K | 3/2/2022 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 4,375 | $108K | 12/7/2021 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 1,750 | $46K | 12/7/2021 | View on chart |
| VCYT | ▼ Sell | Open Market | 4,375 | $174K | 12/7/2021 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,750 | $73K | 12/7/2021 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 4,406 | $26K | 12/6/2021 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 3,750 | $76K | 12/6/2021 | View on chart |
| VCYT | ▼ Sell | Open Market | 3,897 | $141K | 12/6/2021 | View on chart |
| VCYT | ▼ Sell | Open Market | 1,785 | $67K | 12/6/2021 | View on chart |
| VCYT | ▼ Sell | Open Market | 3,550 | $126K | 12/6/2021 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 912 | $36K | 12/2/2021 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 149 | $8K | 11/1/2021 | View on chart |
| VCYT | ▼ Sell | Open Market | 926 | $47K | 9/8/2021 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 4,406 | $26K | 9/7/2021 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 4,375 | $108K | 9/7/2021 | View on chart |
| VCYT | ▲ Buy | Option Exercise | 3,750 | $76K | 9/7/2021 | View on chart |
| VCYT | ▼ Sell | Open Market | 12,034 | $608K | 9/7/2021 | View on chart |
| VCYT | ▼ Sell | Open Market | 497 | $25K | 9/7/2021 | View on chart |
| VCYT | ▼ Sell | Tax Withholding | 912 | $48K | 9/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise
Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.
Veracyte (VCYT) Stock Seen as Undervalued After 107% Rise. Recent coverage notes that Veracyte’s shares have risen more than 100% while still appearing inexpensive relative to its earnings multiple. The company’s trailing P/E of about 30.6 and an analyst consensus target near $58 suggest the market may be pricing in further upside. The stock is currently trading near the lower end of its 52‑week range, close to a support level that has been tested multiple times.